Catalyst Wire Dossier Catalyst Wire Dossier

Cefepime/Nacubactam

cefepime/nacubactam · Meiji Seika Pharma Co., Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Cefepime/Nacubactam, covering 2025-11-25 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales [Phase 3]

See pricing